Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Coherus Biosciences Inc. (CHRS:NASDAQ), powered by AI.
Coherus Biosciences Inc. is currently trading at $1.40. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Coherus Biosciences Inc. on Alpha Lenz.
View Coherus Biosciences Inc.'s valuation metrics on Alpha Lenz.
“Coherus Biosciences Inc.'s ROE is -473.5%. Explore profitability and growth together.”
Ask for details →Coherus Biosciences Inc. is a biotechnology company focused on developing, manufacturing, and commercializing biosimilar products. Biosimilars are highly similar to existing, approved biological medicines with no clinically meaningful differences in terms of safety or efficacy. Coherus Biosciences aims to provide more accessible biological therapeutics in key therapeutic areas such as oncology, ophthalmology, and immunology. By doing so, the company addresses the need for more cost-effective treatment options and aims to contribute to the sustainability of healthcare systems globally. Coherus Biosciences operates within a highly regulated market, collaborating with healthcare providers, payers, and patients to enhance treatment options and availability. Founded in 2010 and headquartered in Redwood City, California, the company leverages its specialized research and development capabilities to expand its portfolio, providing competitive alternatives to high-cost biologics and playing a significant role in the biotechnology and healthcare sectors by fostering innovation and reducing healthcare costs.
“Coherus Biosciences Inc.'s ROE is -473.5%. Explore profitability and growth together.”
Ask for details →Coherus Biosciences Inc. (ticker: CHRS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 228 employees.
The current price is $1.4 with a P/E ratio of -x and P/B of -x.
ROE is -473.47% and operating margin is -429.51%. Annual revenue is $42M.